Molecular Vision: Sodi, Mol Vis 2012; 18:2736-2748. Table 1

Table 1. Clinical details of the VMD patients included in the study (families A-G).

Family	Family member	Sex	Age (years)	Onset (years)	BCVA OD	BCVA OS	Fundus OD	Fundus OS	Notes
A	III-3	F	11	6	0.8	1.0	VL	PV	Unil
A	II-5	M	45	//	1.0	1.0	Norm	Norm
A	II-4	F	42	//	1.0	1.0	Norm	Norm
A	III-4	M	9	//	1.0	1.0	Norm	Norm
A	II-3	F	42	//	0.6	1.0	Norm	Norm	Ambl OD
A	III-1	M	14	//	1.0	1.0	Norm	Norm
A	III-2	F	12	//	1.0	1.0	Norm	Norm
A	I-2	F	78	//	0.5	1.0	GC	GC	Glau OU
B	II-1	M	16	10	0.7	0.9	PH	PH
B	I-1	M	44	39	0.9	1.0	VR	VR
B	I-2	F	40	//	1.0	1.0	Norm	Norm
C	II-1	M	18	8	0.8	0.8	VR	VR	CNV; P
C	I-1	M	54	//	1.0	1.0	Norm	Norm
C	I-2	F	50	//	1.0	1.0	Norm	Norm
D	II-1	M	22	14	0.3	1.0	FI	VL	CNV
D	I-1	M	55	//	1.0	1.0	Norm	Norm
D	I-2	F	57	35	0.4	0.3	AT	AT
E	I-1	M	62	25	0.2	0.2	AT	AT
E	II-1	M	42	//	1.0	1.0	Norm	Norm
F	II-1	F	46	10	0.2	0.2	AT	AT
G	I-2	M	60	29	0.3	0.1	FI	FI
G	II-1	M	27	8	1.0	1.0	VL	VL
G	II-2	F	25	7	1.0	1.0	VL	VL
G	I-3	M	68	35	0.8	0.9	AT	VL	Mult OS
G	II-5	F	28	//	1.0	1.0	Norm	Norm

For each patient the stage of disease is indicated. (BCVA: Best Corrected Visual Acuity; VL: vitelliform lesion; PV: pre-vitelliform lesion; GC: glaucomatous cupping; PH: pseudohypopyon stage; VR: vitelliruptive stage; AT: atrophic stage; FI: fibrotic stage; CNV: previous choroidal neovascularization; P: treated with photodynamic therapy; Unil: unilateral presentation of the disease; Mult: multifocal presentation of the disease; Ambl: Ambliopia; Glau: Glaucoma; OD: right eye; OS: left eye; //: unknown; OU: both eyes).